PT-141 10mg

What is PT-141 (10 mg)?

PT-141 (10 mg), also known as bremelanotide, is a synthetic melanocortin receptor agonist peptide derived from melanocortin analog research. It is primarily investigated for its interaction with melanocortin receptor subtypes in controlled laboratory environments.

PT-141 is being studied for its central melanocortin receptor activity, with a focus on its effects at MC3R and MC4R. These receptors are involved in neuroendocrine and hypothalamic signaling networks, rather than direct peripheral vasodilatory mechanisms. Because of this, PT-141 is often used in experimental models exploring peptide-mediated communication between the central nervous system and endocrine pathways.

The 10 mg format is supplied as a lyophilized powder to support handling and reconstitution for in vitro and preclinical studies. All applications are strictly limited to laboratory research use.

Product Specifications

• CAS Number: 189691-06-3
• Peptide Sequence: Ac-Nle-Asp(1)-His-D-Phe-Arg-Trp-Lys(1)
• Molecular Formula: C₅₀H₆₈N₁₄O₁₀
• Molecular Weight: 1025.182 g/mol
• Subcategory: Sexual Health & Hormonal Peptides
• Purity: ≥95% (verified by HPLC)
• Packaging Format: 10 mg lyophilized powder in sealed research-grade vial
• Storage Conditions: Store at 2–8 °C or frozen at ≤ –20 °C as appropriate. Protect from light and moisture. Minimize room-temperature exposure.
• Intended Use: For Laboratory Research Use Only

Key Characteristics of PT-141 (10 mg)

• Synthetic Melanocortin Analog: Designed to selectively engage melanocortin receptors in experimental models.
• Cyclic Peptide Structure: Contributes to receptor-binding stability and defined signaling activity.
• High Analytical Purity: Typically ≥95%, confirmed using validated chromatographic methods.
• Lyophilized Presentation: Supplied lyophilized to support handling and reconstitution.
• Receptor-Focused Research Tool: Commonly used in neuroendocrine and central signaling studies.
• Batch Consistency: Produced via controlled peptide synthesis for reproducible experimental results.

How PT-141 (10 mg) Supports Research

PT-141 is used in laboratory research to investigate melanocortin receptor activation and downstream intracellular signaling mechanisms. Researchers examine how PT-141 binds to receptor subtypes and how receptor engagement influences secondary messenger pathways, gene expression markers, and neuroendocrine communication processes.

Because melanocortin receptors are involved in central regulatory networks, PT-141 is often incorporated into experimental models studying hypothalamic signaling, peptide–receptor kinetics, and neuropeptide-driven behavioral pathways in preclinical settings. Its defined molecular structure allows controlled assessment of receptor affinity, signaling duration, and comparative activity relative to other melanocortin analogs. All observed biological activity remains limited to investigational research models.

Research Applications & Usage Information

PT-141 (10 mg) is commonly used in laboratory research for:

• Melanocortin receptor (MC3R/MC4R) binding assays
• Neuroendocrine pathway analysis
• Peptide–receptor interaction studies
• Central nervous system signaling models
• Comparative evaluation of melanocortin analog peptides
• In vitro and preclinical studies assessing receptor-mediated signaling

Applications are strictly investigational and conducted within controlled laboratory environments.

Handling and Storage Recommendations

• Store unopened vials at 2–8 °C or frozen at ≤ –20 °C as appropriate. Protect from light and moisture.
• Keep vials tightly sealed until reconstitution to prevent contamination.
• Avoid prolonged exposure to heat, moisture, or direct light.
• After reconstitution, store at 2–8 °C and use according to laboratory protocol.
• Avoid repeated freeze–thaw cycles to maintain peptide integrity and experimental consistency.

Research Use Only Notice

This product is intended for laboratory research use only and is not approved for human or veterinary use. It is not intended for diagnostic, therapeutic, or clinical applications. Any reference to biological activity or potential effects is based solely on preclinical or in-vitro findings and should not be interpreted as validated clinical outcomes. Researchers are responsible for ensuring proper handling, storage, and disposal in accordance with institutional, federal, and international guidelines.

References

1. Edinoff AN, Sanders NM, Lewis KB, et al. Bremelanotide for Treatment of Female Hypoactive Sexual Desire. Neurol Int. 2022;14(1):75-88. Published 2022 Jan 4. doi:10.3390/neurolint14010006
2. Molinoff PB, Shadiack AM, Earle D, Diamond LE, Quon CY. PT-141: a melanocortin agonist for the treatment of sexual dysfunction. Ann N Y Acad Sci. 2003;994:96-102. doi:10.1111/j.1749-6632.2003.tb03167.x
3. Pfaus JG, Sadiq A, Spana C, Clayton AH. The neurobiology of bremelanotide for the treatment of hypoactive sexual desire disorder in premenopausal women. CNS Spectr. 2022;27(3):281-289. doi:10.1017/S109285292100002X